Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Structural Implications of STAT3 and STAT5 SH2 Domain Mutations.
de Araujo ED, Orlova A, Neubauer HA, Bajusz D, Seo HS, Dhe-Paganon S, Keserű GM, Moriggl R, Gunning PT. de Araujo ED, et al. Among authors: moriggl r. Cancers (Basel). 2019 Nov 8;11(11):1757. doi: 10.3390/cancers11111757. Cancers (Basel). 2019. PMID: 31717342 Free PMC article. Review.
Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.
Eiring AM, Page BDG, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Moriggl R, Wilson DJ, Baron R, O'Hare T, Gunning PT, Deininger MW. Eiring AM, et al. Among authors: moriggl r. Leukemia. 2015 Mar;29(3):586-597. doi: 10.1038/leu.2014.245. Epub 2014 Aug 19. Leukemia. 2015. PMID: 25134459 Free PMC article.
STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion.
Gotthardt D, Putz EM, Grundschober E, Prchal-Murphy M, Straka E, Kudweis P, Heller G, Bago-Horvath Z, Witalisz-Siepracka A, Cumaraswamy AA, Gunning PT, Strobl B, Müller M, Moriggl R, Stockmann C, Sexl V. Gotthardt D, et al. Among authors: moriggl r. Cancer Discov. 2016 Apr;6(4):414-29. doi: 10.1158/2159-8290.CD-15-0732. Epub 2016 Feb 12. Cancer Discov. 2016. PMID: 26873347
Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.
Gleixner KV, Schneeweiss M, Eisenwort G, Berger D, Herrmann H, Blatt K, Greiner G, Byrgazov K, Hoermann G, Konopleva M, Waliul I, Cumaraswamy AA, Gunning PT, Maeda H, Moriggl R, Deininger M, Lion T, Andreeff M, Valent P. Gleixner KV, et al. Among authors: moriggl r. Haematologica. 2017 Sep;102(9):1519-1529. doi: 10.3324/haematol.2016.163436. Epub 2017 Jun 8. Haematologica. 2017. PMID: 28596283 Free PMC article.
Tumor target amplification: Implications for nano drug delivery systems.
Seidi K, Neubauer HA, Moriggl R, Jahanban-Esfahlan R, Javaheri T. Seidi K, et al. Among authors: moriggl r. J Control Release. 2018 Apr 10;275:142-161. doi: 10.1016/j.jconrel.2018.02.020. Epub 2018 Feb 16. J Control Release. 2018. PMID: 29454742 Review.
Pharmacologic inhibition of STAT5 in acute myeloid leukemia.
Wingelhofer B, Maurer B, Heyes EC, Cumaraswamy AA, Berger-Becvar A, de Araujo ED, Orlova A, Freund P, Ruge F, Park J, Tin G, Ahmar S, Lardeau CH, Sadovnik I, Bajusz D, Keserű GM, Grebien F, Kubicek S, Valent P, Gunning PT, Moriggl R. Wingelhofer B, et al. Among authors: moriggl r. Leukemia. 2018 May;32(5):1135-1146. doi: 10.1038/s41375-017-0005-9. Epub 2018 Feb 2. Leukemia. 2018. PMID: 29472718 Free PMC article.
221 results